BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2013

View Archived Issues

Uncovering the mechanism behind the chemotherapeutic resistance that arises in glioblastoma

Read More

Preliminary phase I data presented for Shionogi's S-222611

Read More

NCI awards contract for melanoma diagnostic, U of Michigan offers new prostate cancer test

Read More

Scientists discover new antibodies binding to TGF-beta-1

Read More

Galaxy Biotech patents novel bispecific antibodies for cancer

Read More

DetectoGen presents new polypeptides as vaccines for leishmaniasis

Read More

Takeda Pharmaceutical synthesizes novel 5-HT2C receptor agonists

Read More

Japanese team prepares new BTK inhibitors

Read More

Asahi Kasei Pharma and Vernalis form autoimmune drug discovery collaboration

Read More

Scancell provides update on its drug discovery pipeline

Read More

Aerial BioPharma to accelerate development of ADX-N05

Read More

First demonstration of vaccine-mediated elimination of SIV infection

Read More

Diabetes agents found to improve behavioral and pathological signs of Alzheimer's disease

Read More

Tri-Institutional Therapeutics Discovery Institute and Takeda form drug discovery partnership

Read More

Xencor's XmAb-5871 advances to second phase of rheumatoid arthritis study

Read More

FDA and EMA accept OMS-302 marketing applications for review

Read More

Actavis completes acquisition of Warner Chilcott

Read More

Xention and Servier form cardiovascular collaboration for XEN-D0103

Read More

Moderna Therapeutics receives DARPA grant to develop messenger RNA therapeutics

Read More

Valneva enters into license agreement with International AIDS Vaccine Initiative

Read More

Heat Biologics files IND for HS-410 in bladder cancer

Read More

Amgen investigates metabolism across species of potent mTOR inhibitor

Read More

AZD-9291 shows promising activity in NSCLC patients

Read More

Vemurafenib shows promise for VEGFR-2 inhibitor-naive patients with PTC

Read More

Eisai gains European approval for use of antiepileptic agent in pediatric patients

Read More

StemCells gains IND clearance to expand clinical testing of HuCNS-SC in spinal cord injury to U.S.

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing